Market Cap
$225.1M
CGEN
COMPUGEN LTD
$2.34 ▲ +0.00%
Prev close $2.34Market cap$225.1M
12-mo target$4.60 (+96.6%)
Insider Selling Cluster (2 insiders) Biotech & Drug Discovery
Snapshot
The big-picture read on CGEN right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Insider Activity
$0.00 buy / $126.3K sell
Insider Net $
-$126.3K
Social Sentiment
60° Warm
SEC Reports
8
Price chart 30d -11.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 other
Aug 3, 2026 SEC Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-s
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by Gilead
6-K — Impact 4/10
Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The meeting will cover the ele
6-K — Impact 2/10
Jul 29, 2026 Insider
Kredo Russo Sharon was granted 18,000 shares
SVP, Research & Discovery
Jul 29, 2026 Insider
Ferre Pierre was granted 70,000 shares
Chief Operating Officer
Jul 29, 2026 Insider
Jun 9, 2026 SEC Ophir Eran was granted 200,000 shares
President and CEO
Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective by the SEC on June 8, 2
EFFECT — Impact 3/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 21, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Apr 7, 2026 | Lake Street | INITIATE | Buy | 45% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% |
Price targets
Where 5 covering analysts think CGEN trades over the next 12 months.
$4.60 +96.6% upside Strong Buy
Current$2.34 Low$4.00 Median$4.00 High$6.00 5 analysts
$4.00$6.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 8 neutral · avg impact 2.9/10.
NEUTRAL6-K4/10
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (
Aug 3, 2026
NEUTRAL6-K2/10
Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The meetin
Aug 3, 2026
NEUTRALEFFECT3/10
Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective by
Jun 9, 2026
NEUTRAL6-K4/10
Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M
May 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
other
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in
Sep 8, 2026
other
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in
Aug 31, 2026
short_interest_report
Short Interest: CGEN down 23% to 2.3M shares
Settlement 2026-08-31 | Days to cover: 6.11 | ≈2.48% of shares outstanding (est.)
Aug 14, 2026
short_interest_report
Short Interest: CGEN up 8% to 3.0M shares
Settlement 2026-08-14 | Days to cover: 10.01 | ≈3.21% of shares outstanding (est.)
Aug 3, 2026
earnings_calendar
CGEN Q2 2026 Earnings Scheduled — 2026-08-03
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.09 | $-0.10–$-0.07 | -23.8% | -2.0% | — | $0.0B | 3 |
| Next Q | $-0.09 | $-0.10–$-0.07 | -114.5% | -2.0% | — | $0.0B | 3 |
| Current FY | $-0.33 | $-0.35–$-0.30 | -186.8% | +2.9% | 1↑ 0↓ | $0.0B | 3 |
| Next FY | $-0.37 | $-0.41–$-0.31 | -11.1% | -0.5% | 1↑ 0↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.087 | — |
| 7d ago | $-0.085 | -0.002 |
| 30d ago | $-0.085 | -0.002 |
| 60d ago | $-0.085 | -0.002 |
| 90d ago | $-0.080 | -0.007 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 49 transactions. Net -$126.3K — $0.00 bought, $126.3K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | Kredo Russo Sharon | SVP, Research & Discovery | AWARD | 18,000 | — | — |
| Jul 29, 2026 | Ferre Pierre | Chief Operating Officer | AWARD | 70,000 | — | — |
| Jul 29, 2026 | Ophir Eran | President and CEO | AWARD | 200,000 | — | — |
| Jul 29, 2026 | Livnat Savitzky Kinneret | Director | AWARD | 7,500 | — | — |
| Jul 29, 2026 | ZWEIFACH SANFORD S | Director | AWARD | 10,000 | — | — |
| Jul 29, 2026 | Halevy Gilead | Director | AWARD | 7,500 | — | — |
| Jul 29, 2026 | ZWEIFACH SANFORD S | Director | AWARD | 7,500 | — | — |
| Jul 29, 2026 | Halevy Gilead | Director | AWARD | 10,000 | — | — |
| Jul 29, 2026 | Hukkelhoven Mathias | Director | AWARD | 7,500 | — | — |
| Jul 29, 2026 | Hukkelhoven Mathias | Director | AWARD | 10,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CGEN.
Shares short
2,366,980
Settlement Sep 15, 2026
Change vs prior
+0.8%
Semi-monthly cycle
Days to cover
12.0
At avg daily volume
Of shares outstanding
≈2.5%
Estimate — not % of float
All CGEN filing & press-release reports (8)
- 6-K reportAug 3, 2026
- 6-K reportAug 3, 2026
- EFFECT reportJun 9, 2026
- 6-K reportMay 18, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 15, 2026
- 144 reportApr 13, 2026
- CLUSTER reportApr 3, 2026